通过Levilactobacillus brevis AK19B生产玛-氨基黄油酸:使用盒式设计进行菌株特征和过程优化
Habibe Memiş1, Aybike Kamiloğlu2
1Faculty of Engineering, Food Engineering Department, Bayburt University, Bayburt, 69000, Turkey.
Probiotics and antimicrobial proteins
|March 12, 2026
概括
益生菌细菌Levilactobacillus brevis AK19B,由于其抗氧化和植物酶活动,显示出功能性食品的潜力. 优化条件被发现可以显著增强其玛氨基黄油酸 (GABA) 产量.
科学领域:
- 微生物学 微生物学
- 生物技术是生物技术.
- 食品科学 食品科学 食品科学
背景情况:
- 莱维拉ctobacillus brevis AK19B是一种乳酸细菌,具有证明的益生菌潜力.
- 这种菌株表现出有价值的植物酶活性,抗氧化特性和在胃肠道条件下强度.
- 胺黄油酸 (GABA) 是一种具有健康益处的神经递质,其由益生菌产生的兴趣很大.
研究的目的:
- 为了优化由Levilactobacillus brevis AK19B.B.产生的胺黄油酸 (GABA) 的产生.
- 为了研究单谷氨酸 (MSG) 度,NaCl度,pH和温度对GABA合成的影响.
- 为潜在的工业应用确定最大限度地提高GABA产量的最佳条件.
主要方法:
- 采用Box-Behnken设计来研究四个因素 (MSG度,NaCl度,pH,温度) 对GABA生产的影响.
- 使用响应表面方法来建模这些因素之间的相互作用,并预测最佳条件.
- 评估了L. brevis AK19B在富含胆汁盐的环境中的生存能力,以确认其益生菌强度.
主要成果:
- 单谷氨酸 (MSG) 度,NaCl度,pH值和温度显著影响了L. brevis AK19B的GABA合成.
- 一个二级响应表面模型准确地描述了测试因素之间的相互作用.
- 确定GABA生产的最佳条件为pH5.136,297mMMSG,26°C和2.82%NaCl,产生预测的43.85mg/ml的GABA.
结论:
- Levilactobacillus brevis AK19B是一种强大的益生菌候选物,具有功能性食品应用的巨大潜力.
- 该研究通过确定关键影响因素及其最佳水平,成功优化了GABA生产.
- 这些发现支持使用L. brevis AK19B进行工业规模的GABA生物合成.
相关概念视频
01:29Microbes in Food Production
407
Microbial fermentation is central to food biotechnology, enhancing flavor, texture, preservation, and stability. Fermentative microorganisms metabolize carbohydrates into organic acids, alcohols, and other metabolites that inhibit spoilage organisms and improve digestibility while contributing distinctive sensory qualities.In baking, amylases naturally present in flour hydrolyze starch into monosaccharides such as glucose, which Saccharomyces cerevisiae ferments anaerobically. Through...
407
01:22Bioreactor Controls-III
70
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
70
01:27Upstream Processing
102
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
102
01:25Production of Organic Acids
111
Lactic acid, an important organic acid extensively applied in food, pharmaceutical, and biodegradable polymer industries, is primarily produced via microbial fermentation. This method is favored over chemical synthesis due to its environmental sustainability and capacity for enantiomerically pure product formation. Among various microbial processes, the fermentation of starch-based substrates stands out due to the abundance and renewability of raw materials like corn and potatoes.Hydrolysis of...
111
01:27Production of Antibiotics
281
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
281
01:30Production of Pharmaceuticals
99
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
99